Austin Miller

Asst Professor of Oncology, Biostatistics and Bioinformatics

Roswell Park Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Austin Miller is an Assistant Professor of Oncology, Biostatistics and Bioinformatics at Roswell Park Cancer Institute in the United States. His research primarily focuses on ovarian cancer, particularly the evaluation of various treatment regimens and the role of genomic factors in cancer immunotherapy. He has contributed to several significant studies examining therapies for platinum-resistant ovarian cancer and the impact of lifestyle interventions on cancer survival outcomes.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (6)

Samuel Mok

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Christina Washington

University of Oklahoma Health Sciences Center

UNITED STATES

View details

C Simon Herrington

Professor

University of Edinburgh

UNITED KINGDOM

View details

Emese Zsiros

Associate Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES

View details

Craig Freyer

Hospital of the University of Pennsylvania

UNITED STATES

View details

Kevin Eng

Research Assistant Professor

State University of New York at Buffalo

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Austin Miller

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

Improving the Estimation of Prediction Increment Measures in Logistic and Survival Analysis

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors

Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.

Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.

Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)

Survival with Cemiplimab in Recurrent Cervical Cancer.

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.

Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.

Collaborators (6)

Samuel Mok

Christina Washington

C Simon Herrington

Emese Zsiros

Craig Freyer

Kevin Eng

Make your next move.